Observational studyEndocrine2025
Increase in visceral adipose tissue and altered metabolic profile in transgender men but not in transgender women one year after starting gender-affirming hormonal therapy.
Observational study in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04508231 (Metabolic Consequences of Cross-sex Hormonal Treatment in Transgender Persons), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metabolic Consequences of Cross-sex Hormonal Treatment in Transgender Persons
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextIncrease in body fat and dyslipidemia have been reported in persons receiving gender-affirming hormone therapy (GAHT). However, little is known whether these changes are associated with a pro-inflammatory state.
objectiveTo study the relationship between changes in body composition, cardiometabolic parameters and systemic inflammatory indices in transgender persons at baseline and one year after starting GAHT.
methodA single center retrospective study including 50 assigned female at birth (AFAB) (median age 21.5 years) and 37 assigned male at birth (AMAB) persons (median age 29 years) with data separated by a 1-year period.
resultsTestosterone therapy in AFAB persons led to a significant increase in VAT (P = 0.0006), trunk/limb ratio (P < 0.001), uric acid (P < 0.001), LDL-cholesterol (P < 0.05) and a significant decrease in HDL-cholesterol (P < 0.05). There were no changes in systemic inflammatory indices. Results of the final regression models indicated that increase in uric acid explained 33.2% of the variation in VAT [F(1,15) = 7.458; adjusted R square 0.332; P = 0.015]. In AMAB persons receiving GAHT, we observed an increase in total body fat (P = 0.002), fat mass index (P = 0.001) and HDL cholesterol (P < 0.05). The aspartate transaminase to lymphocyte ratio index decreased (P < 0.05) one year after the start of treatment.
conclusionGAHT in the AFAB persons led to a significant increase in VAT and altered metabolic profile. There were no changes in systemic inflammatory indices. The AMAB people presented a non-deleterious cardiometabolic phenotype. CLINICAL
trial registrationThe study is registered at ClinicalTrials.gov (NCT04508231).
Indexed as
Identifiers
40495044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.